Journal article

Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Ursula Schmidt-Erfurth, Bora Eldem, Robyn Guymer, Jean-Francois Korobelnik, Reinier O Schlingemann, Ruth Axer-Siegel, Peter Wiedemann, Christian Simader, Margarita Gekkieva, Andreas Weichselberger

Ophthalmology | ELSEVIER SCIENCE INC | Published : 2011

DOI: 10.1016/j.ophtha.2010.09.004

Grants

Funding Acknowledgements

Peter Wiedemann - Lecture Fee - Novartis Pharmaceutical CorporationSupported by Novartis Pharma, AG, Switzerland.

Citation metrics

256Web of Science
294Scopus
303Dimensions

Keywords

Excite Study Group
Drug Administration Schedule
Humans
Antibodies, Monoclonal
Science & Technology
Retina
Choroidal Neovascularization
Male
Macular Degeneration
Antibodies, Monoclonal, Humanized
Middle Aged
Ophthalmology
Treatment Outcome
Ranibizumab
Vascular Endothelial Growth Factor a
Aged
Visual Acuity
Fluorescein Angiography
Intravitreal Injections
Endothelial Growth-Factor
Verteporfin
Angiogenesis Inhibitors
Life Sciences & Biomedicine
Tomography, Optical Coherence
Therapy
Female
Aged, 80 and Over
Double-Blind Method
Antigen